Cargando…

Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century

Iron overload used to be considered rare in hemodialysis patients but its clinical frequency is now increasingly realized. The liver is the main site of iron storage and the liver iron concentration (LIC) is closely correlated with total iron stores in patients with secondary hemosideroses and genet...

Descripción completa

Detalles Bibliográficos
Autores principales: Rostoker, Guy, Vaziri, Nosratola D., Fishbane, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848337/
https://www.ncbi.nlm.nih.gov/pubmed/27091216
http://dx.doi.org/10.1007/s40265-016-0569-0
_version_ 1782429321095282688
author Rostoker, Guy
Vaziri, Nosratola D.
Fishbane, Steven
author_facet Rostoker, Guy
Vaziri, Nosratola D.
Fishbane, Steven
author_sort Rostoker, Guy
collection PubMed
description Iron overload used to be considered rare in hemodialysis patients but its clinical frequency is now increasingly realized. The liver is the main site of iron storage and the liver iron concentration (LIC) is closely correlated with total iron stores in patients with secondary hemosideroses and genetic hemochromatosis. Magnetic resonance imaging is now the gold standard method for LIC estimation and monitoring in non-renal patients. Studies of LIC in hemodialysis patients by quantitative magnetic resonance imaging and magnetic susceptometry have demonstrated a strong relation between the risk of iron overload and the use of intravenous (IV) iron products prescribed at doses determined by the iron biomarker cutoffs contained in current anemia management guidelines. These findings have challenged the validity of both iron biomarker cutoffs and current clinical guidelines, especially with respect to recommended IV iron doses. Three long-term observational studies have recently suggested that excessive IV iron doses may be associated with an increased risk of cardiovascular events and death in hemodialysis patients. We postulate that iatrogenic iron overload in the era of erythropoiesis-stimulating agents may silently increase complications in dialysis patients without creating frank clinical signs and symptoms. High hepcidin-25 levels were recently linked to fatal and nonfatal cardiovascular events in dialysis patients. It is therefore tempting to postulate that the main pathophysiological pathway leading to these events may involve the pleiotropic master hormone hepcidin (synergized by fibroblast growth factor 23), which regulates iron metabolism. Oxidative stress as a result of IV iron infusions and iron overload, by releasing labile non-transferrin-bound iron, might represent a ‘second hit’ on the vascular bed. Finally, iron deposition in the myocardium of patients with severe iron overload might also play a role in the pathogenesis of sudden death in some patients.
format Online
Article
Text
id pubmed-4848337
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-48483372016-05-12 Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century Rostoker, Guy Vaziri, Nosratola D. Fishbane, Steven Drugs Current Opinion Iron overload used to be considered rare in hemodialysis patients but its clinical frequency is now increasingly realized. The liver is the main site of iron storage and the liver iron concentration (LIC) is closely correlated with total iron stores in patients with secondary hemosideroses and genetic hemochromatosis. Magnetic resonance imaging is now the gold standard method for LIC estimation and monitoring in non-renal patients. Studies of LIC in hemodialysis patients by quantitative magnetic resonance imaging and magnetic susceptometry have demonstrated a strong relation between the risk of iron overload and the use of intravenous (IV) iron products prescribed at doses determined by the iron biomarker cutoffs contained in current anemia management guidelines. These findings have challenged the validity of both iron biomarker cutoffs and current clinical guidelines, especially with respect to recommended IV iron doses. Three long-term observational studies have recently suggested that excessive IV iron doses may be associated with an increased risk of cardiovascular events and death in hemodialysis patients. We postulate that iatrogenic iron overload in the era of erythropoiesis-stimulating agents may silently increase complications in dialysis patients without creating frank clinical signs and symptoms. High hepcidin-25 levels were recently linked to fatal and nonfatal cardiovascular events in dialysis patients. It is therefore tempting to postulate that the main pathophysiological pathway leading to these events may involve the pleiotropic master hormone hepcidin (synergized by fibroblast growth factor 23), which regulates iron metabolism. Oxidative stress as a result of IV iron infusions and iron overload, by releasing labile non-transferrin-bound iron, might represent a ‘second hit’ on the vascular bed. Finally, iron deposition in the myocardium of patients with severe iron overload might also play a role in the pathogenesis of sudden death in some patients. Springer International Publishing 2016-04-18 2016 /pmc/articles/PMC4848337/ /pubmed/27091216 http://dx.doi.org/10.1007/s40265-016-0569-0 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Current Opinion
Rostoker, Guy
Vaziri, Nosratola D.
Fishbane, Steven
Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century
title Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century
title_full Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century
title_fullStr Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century
title_full_unstemmed Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century
title_short Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century
title_sort iatrogenic iron overload in dialysis patients at the beginning of the 21st century
topic Current Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848337/
https://www.ncbi.nlm.nih.gov/pubmed/27091216
http://dx.doi.org/10.1007/s40265-016-0569-0
work_keys_str_mv AT rostokerguy iatrogenicironoverloadindialysispatientsatthebeginningofthe21stcentury
AT vazirinosratolad iatrogenicironoverloadindialysispatientsatthebeginningofthe21stcentury
AT fishbanesteven iatrogenicironoverloadindialysispatientsatthebeginningofthe21stcentury